Regeneron Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Regeneron (NASDAQ: REGN) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026.
The live webcast is scheduled for 2:15 p.m. Pacific Time / 5:15 p.m. Eastern Time and can be accessed from the company’s Investors & Media page at http://investor.regeneron.com/events-and-presentations. A replay and transcript will be archived on the company website for at least 30 days.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, REGN gained 0.75%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
REGN gained 2.57% with strong volume, while key biotech peers like VRTX (+2.09%), INSM (+3.89%), and ONC (+2.55%) also rose, suggesting generally constructive biotech sentiment rather than a tightly linked sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 07 | Clinical trial update | Positive | -2.1% | Encouraging Phase 1/2 Lynozyfic NDMM data with high VGPR+ and MRD negativity. |
| Dec 01 | Strategic collaboration | Positive | -3.9% | Global TSRA-196 gene-editing partnership for AATD with upfront and milestones. |
| Nov 25 | Regulatory approval EU | Positive | +3.4% | EU approval for Dupixent in CSU based on LIBERTY-CUPID Phase 3 data. |
| Nov 19 | Regulatory approval US | Positive | -3.1% | FDA approval of EYLEA HD 8 mg for RVO and broader monthly dosing option. |
| Nov 19 | Regulatory approval EU | Positive | -3.1% | EU approval of Libtayo as first adjuvant immunotherapy for high-risk CSCC. |
Recent history shows predominantly positive clinical and regulatory news often followed by negative price reactions, suggesting a pattern of selling into good news, with only one of five events aligning positively.
Over the past two months, REGN reported multiple positive milestones: strong Phase 1/2 data for Lynozyfic™ in NDMM on Dec 7, 2025 (24h move -2.1%), a TSRA-196 gene-editing collaboration on Dec 1 (-3.86%), EU approval for Dupixent® in CSU on Nov 25 (+3.4%), and FDA/EU approvals for EYLEA HD® and Libtayo® on Nov 19 (each -3.11%). Today’s conference presentation notice follows a stretch where fundamentally positive updates often met with selling pressure.
Market Pulse Summary
This announcement outlines REGN’s webcasted presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, with access via the company’s investor site and a replay available for at least 30 days. In context of recent clinical and regulatory milestones, investors may focus on how management frames the pipeline, commercial priorities, and capital allocation. Follow-up disclosures or guidance from the event may be more informative than this scheduling notice alone.
AI-generated analysis. Not financial advice.
TARRYTOWN, N.Y., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. The presentation is scheduled for 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time) and may be accessed from the "Investors & Media" page of Regeneron's website at http://investor.regeneron.com/events-and-presentations. A replay and transcript of the webcast will be archived on the Company's website for at least 30 days.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.
Contact Information:
Investor Relations
Ryan Crowe
914.847.8790
ryan.crowe@regeneron.com
Corporate Communications
Christina Chan
914.847.8827
christina.chan@regeneron.com
FAQ
When will Regeneron (REGN) present at the J.P. Morgan Healthcare Conference in 2026?
How can investors watch the Regeneron (REGN) webcast for the J.P. Morgan presentation?
Will there be a replay or transcript of Regeneron’s (REGN) January 12, 2026 presentation?
What time is Regeneron’s (REGN) J.P. Morgan presentation in Eastern Time?
Where on Regeneron’s site is the J.P. Morgan webcast posted?
